Regulatory mechanism and therapeutic potentials of naringin against inflammatory disorders

Peng, Yuan; Qu, Ruyi; Xu, Shuqin; Bi, Hongsheng; Guo, Dadong

doi:10.1016/j.heliyon.2024.e24619

Cited by 2 publications

(1 citation statement)

References 191 publications

(219 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the impact of neobavaisoflavone on blood pressure has not been explored, necessitating further research. Naringin is a flavanone glycoside with pharmacological effects, including antioxidant, lipid-lowering, anticancer, and inhibition of cytochrome P450 enzymes ( Peng et al, 2024 ; Effat et al, 2024 ). Previous studies have reported that a long-term increase in the intake of flavonoids can effectively reduce the incidence rate of cardiovascular diseases in the population.…”

Section: Discussionmentioning

confidence: 99%

Investigation of the molecular mechanism of Smilax glabra Roxb. in treating hypertension based on proteomics and bioinformatics

Yang,

Qian,

Yang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

BackgroundSmilax glabra Roxb. (named tufuling in Chinese, SGR) has both medicinal and edible value. SGR has obvious pharmacological activity, especially in anti-inflammation and treating immune system diseases. This study investigated differential protein expression and its relationship with immune infiltration in hypertension treated with SGR using proteomics and bioinformatics.MethodsN-Nitro L-arginine methyl ester (L-NAME) was used to replicate the hypertension model, with SGR administered by gavage for 4 weeks, and the systolic and diastolic blood pressure in each group of rats was measured using the tail-cuff method every 7 days. Furthermore, enzyme-linked immunosorbent assay (ELISA) was used to determine the serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) expressions in each group, followed by the detection of protein expression in rat liver samples using the tandem mass tag (TMT) technique. Additionally, hub targets were output using Cytoscape 3.9.1 software, and ALDH2 expression in the liver and serum in each group of rats was detected by ELISA. Moreover, R4.3.0 software was used to evaluate the relationship between acetaldehyde dehydrogenase 2 (ALDH2) and immune cells, and ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) was performed to identify the components of SGR. Furthermore, the association between components of SGR and ALDH2 was analyzed with molecular docking and LigPlot1.4.5 software.ResultsCompared with the model group (L-NAME), SGR at high and medium doses reduced systolic and diastolic blood pressure while reducing TC, TG, and LDL-C levels and increasing HDL-C levels in hypertensive rats (p < 0.05). Moreover, 92 differentially expressed proteins (DEPs) were identified using TMT. These DEPs participated in peroxisome functioning, fatty acid degradation, and other signaling pathways, with ALDH2 being the core target and correlated with various immune cells. In addition, 18 components were determined in SGR, with 8 compounds binding to ALDH2. Molecular docking was performed to confirm that SGR played a role in hypertension based on the combined action of multiple components.ConclusionIn conclusion, SGR has an antihypertensive effect on L-NAME-induced hypertension, with ALDH2 as its hub target. SGR may regulate neutrophil, regulatory T cell, and other cells’ infiltration by targeting ALDH2, thereby contributing to the treatment of hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%